Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

47 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Response to raltegravir-based salvage therapy in HIV-infected patients with hepatitis C virus or hepatitis B virus coinfection.
Weimer LE, Fragola V, Floridia M, Guaraldi G, Ladisa N, Francisci D, Bellagamba R, Degli Antoni A, Parruti G, Giacometti A, Manconi PE, Vivarelli A, D'Ettorre G, Mura MS, Cicalini S, Preziosi R, Sighinolfi L, Verucchi G, Libertone R, Tavio M, Sarmati L, Bucciardini R; ISS-NIA Study Group. Weimer LE, et al. Among authors: fragola v. J Antimicrob Chemother. 2013 Jan;68(1):193-9. doi: 10.1093/jac/dks341. Epub 2012 Sep 14. J Antimicrob Chemother. 2013. PMID: 22984206 Free PMC article.
Virological failure at one year in triple-class experienced patients switching to raltegravir-based regimens is not predicted by baseline factors.
Bucciardini R, D'Ettorre G, Baroncelli S, Ceccarelli G, Parruti G, Weimer LE, Fragola V, Galluzzo CM, Pirillo MF, Lucattini S, Bellagamba R, Francisci D, Ladisa N, Degli Antoni A, Guaraldi G, Manconi PE, Vullo V, Preziosi R, Cirioni O, Verucchi G, Floridia M; ISS-NIA study group. Bucciardini R, et al. Among authors: fragola v. Int J STD AIDS. 2012 Jul;23(7):459-63. doi: 10.1258/ijsa.2012.011391. Int J STD AIDS. 2012. PMID: 22843997 Clinical Trial.
Hospitalizations and costs of treatment for protease inhibitor-based regimens in patients with very advanced HIV-infection (CD4 < 50/mm(3)).
Floridia M, Massella M, Bucciardini R, Perucci CA, Rossi L, Tomino C, Fragola V, Ricciardulli D, Galluzzo CM, Giannini G, Pirillo MF, Andreotti M, Mirra M, Vella S. Floridia M, et al. Among authors: fragola v. HIV Clin Trials. 2000 Sep-Oct;1(2):9-16. doi: 10.1310/6ulm-xyb7-h4xp-bhfj. HIV Clin Trials. 2000. PMID: 11590493 Clinical Trial.
HIV-related morbidity and mortality in patients starting protease inhibitors in very advanced HIV disease (CD4 count of < 50 cells/microL): an analysis of 338 clinical events from a randomized clinical trial.
Floridia M, Fragola V, Galluzzo CM, Giannini G, Pirillo MF, Andreotti M, Tomino C, Vella S. Floridia M, et al. Among authors: fragola v. HIV Med. 2002 Apr;3(2):75-84. doi: 10.1046/j.1468-1293.2002.00104.x. HIV Med. 2002. PMID: 12010353 Free article. Clinical Trial.
Risk factors and occurrence of rash in HIV-positive patients not receiving nonnucleoside reverse transcriptase inhibitor: data from a randomized study evaluating use of protease inhibitors in nucleoside-experienced patients with very low CD4 levels (<50 cells/microL).
Floridia M, Bucciardini R, Fragola V, Galluzzo CM, Giannini G, Pirillo MF, Amici R, Andreotti M, Ricciardulli D, Tomino C, Vella S; ISS-IP1 study group. Floridia M, et al. Among authors: fragola v. HIV Med. 2004 Jan;5(1):1-10. doi: 10.1111/j.1468-1293.2004.00177.x. HIV Med. 2004. PMID: 14731162 Free article. Clinical Trial.
A reduced grade of liver fibro-steatosis after raltegravir, maraviroc and fosamprenavir in an HIV/HCV co-infected patient with chronic hepatitis, cardiomyopathy, intolerance to nelfinavir and a marked increase of serum creatine phosphokinase levels probably related to integrase inhibitor use.
Degli Antoni A, Weimer LE, Manfredi R, Fragola V, Ferrari C. Degli Antoni A, et al. Among authors: fragola v. West Indian Med J. 2012 Dec;61(9):932-6. doi: 10.7727/wimj.2011.194. West Indian Med J. 2012. PMID: 24020238
HIV-1 coreceptor switch during 2 years of structured treatment interruptions.
Baroncelli S, Galluzzo CM, Andreotti M, Pirillo MF, Fragola V, Weimer LE, Giuliano M, Vella S, Palmisano L. Baroncelli S, et al. Among authors: fragola v. Eur J Clin Microbiol Infect Dis. 2013 Dec;32(12):1565-70. doi: 10.1007/s10096-013-1911-z. Epub 2013 Jul 4. Eur J Clin Microbiol Infect Dis. 2013. PMID: 24213914 Clinical Trial.
Sustained increase of serum creatine phosphokinase levels and progressive muscle abnormalities associated with raltegravir use during 32-week follow-up in an HIV-1 experienced patient on simplified HAART regimen, intolerant to protease inhibitors and abacavir: a case report.
Cirioni O, Weimer LE, Fragola V, Giacometti A, Gabrielli E, Marchionni E, Massella M, Barchiesi F. Cirioni O, et al. Among authors: fragola v. West Indian Med J. 2013;62(4):377-9. doi: 10.7727/wimj.2011.193. West Indian Med J. 2013. PMID: 24756601
A Simplified HAART Regimen with Raltegravir and Lamivudine, and Pharmacokinetic Interactions with a Combined Immunosuppressive Therapy with Tacrolimus and Everolimus in an HIV/HCV/HBV/HDV Patient after Liver Transplantation.
Cirioni O, Weimer LE, Fragola V, Giacometti A, Ancarani F, Maracci M, Gabrielli E, Marchionni E, Pirillo MF, Vella S. Cirioni O, et al. Among authors: fragola v. West Indian Med J. 2014 Dec;63(7):779-84. doi: 10.7727/wimj.2013.264. Epub 2013 Sep 3. West Indian Med J. 2014. PMID: 25867565 Free PMC article.
47 results